Movement Alert|Legend Biotech Falls 5.37% in Regular Trading, Target Cuts Extended After Quarterly Results

Market Focus11-14

On November 14, Legend Biotech fell 5.37% in Regular Trading, trading at $17.5 per share, with turnover of $40.1981 million.

The move was tied to continued post-earnings target price reductions and a fresh rating action from sell-side analysts. The latest update showed Evercore ISI downgrading the stock to In Line, after earlier cuts from RBC to $50, Morgan Stanley to $43, Oppenheimer to $25, and Barclays to $61.

Background results released on November 10 were mixed: third-quarter net profit reached $51.7 million, reversing from a year-earlier loss, while CARVYKTI net sales rose 36% year over year to about $710 million. However, quarterly revenue of $359.5 million came in slightly below market expectations, helping drive the cautious analyst response despite improved profitability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment